A Dendritic Cell (DC) microRNA signature predicts clinical outcome in Melanoma Patients treated with DC vaccine
Year: 2013
Type: article
Abstract: Event Abstract Back to Event A Dendritic Cell (DC) microRNA signature predicts clinical outcome in Melanoma Patients treated with DC vaccine Laura Fiammenghi1*, Erika Bandini2, Francesca Fanini3, Massimiliano Petrini1, Elena Pancisi1, Anna M. Granato1, Valentina Ancarani1, Laura Ridolfi1, Massimo Guidoboni1 and Muller Fabbri3, 4 1 IRCCS- IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Immunology Department, Italy 2 IOR Istituto Oncologico Romagnolo, Italy 3 IRCCS IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Gene Therapy, Italy 4 Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Saban Research Institute, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Department of Molecular Microbiology and Immunology, United States Background: MicroRNAs (miRNAs) are short non-coding RNAs with gene regulatory functions, whose expression is de-regulated in melanoma. It has been reported that patients treated with DC vaccine have a better clinical outcome and a longer overall survival if positive to the delayed-type hypersensitivity (DTH) cutaneous test. The present preliminary study aims to observe whether a different expression of miRNAs occurs in iDC and mDC of metastatic melanoma patients, and whether this expression correlates with the response to treatment, evaluated by the DTH test. Methods: iDC and mDC were collected from 10 patients. DC maturation was obtained with a standard cocktail of cytokines (PGE2, IL-6, TNFa, IL-1b). Total RNA was extracted and hybridized with the 4.0 version of the non-coding RNA array developed at the Ohio State University, which is able to determine the expression of 476 different human miRNAs. Results: We identified a signature of 24 de-regulated miRNAs (10 down- and 14 up-regulated) in iDC of DTH-positive patients (better prognosis) versus DTH-negative patients (worse prognosis), and a signature of 31 de-regulated miRNAs (9 down- and 22 up-regulated) in mDC of DTH-positive versus DTH-negative patients. Interestingly, 5 miRNAs (miR-182, miR-150, miR-330-5p, miR-548-3p, miR-556-3p) were common to the two signatures. Conclusions: Our study indicates that miRNome aberrations at the DC level may account for a different response to treatment, and that miRNA expression in iDC and mDC can suggest which patients will benefit of a DC vaccination. Keywords: Dendritic Cells, miRNA, Melanoma, DC vaccination, DTH Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013. Presentation Type: Abstract Topic: Translational immunology and immune intervention Citation: Fiammenghi L, Bandini E, Fanini F, Petrini M, Pancisi E, Granato AM, Ancarani V, Ridolfi L, Guidoboni M and Fabbri M (2013). A Dendritic Cell (DC) microRNA signature predicts clinical outcome in Melanoma Patients treated with DC vaccine. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00477 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 28 Mar 2013; Published Online: 22 Aug 2013. * Correspondence: Dr. Laura Fiammenghi, IRCCS- IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Immunology Department, Meldola-Forlì, FC, 470121, Italy, [email protected] Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Laura Fiammenghi Erika Bandini Francesca Fanini Massimiliano Petrini Elena Pancisi Anna M Granato Valentina Ancarani Laura Ridolfi Massimo Guidoboni Muller Fabbri Google Laura Fiammenghi Erika Bandini Francesca Fanini Massimiliano Petrini Elena Pancisi Anna M Granato Valentina Ancarani Laura Ridolfi Massimo Guidoboni Muller Fabbri Google Scholar Laura Fiammenghi Erika Bandini Francesca Fanini Massimiliano Petrini Elena Pancisi Anna M Granato Valentina Ancarani Laura Ridolfi Massimo Guidoboni Muller Fabbri PubMed Laura Fiammenghi Erika Bandini Francesca Fanini Massimiliano Petrini Elena Pancisi Anna M Granato Valentina Ancarani Laura Ridolfi Massimo Guidoboni Muller Fabbri Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
Source: Frontiers in Immunology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W2321344755